Disposition of 495 shares by Mcneill Jonathan of Dyne Therapeutics at 28.59 subject to Rule 16b-3

DYN Stock  USD 23.72  0.75  3.06%   
About 68% of Dyne Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dyne Therapeutics suggests that many traders are alarmed. Dyne Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Dyne Therapeutics. Many technical investors use Dyne Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Dyne Therapeutics Officer: Chief Business Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 495 common stock at 28.59 of Dyne Therapeutics by Mcneill Jonathan on 16th of May 2024. This event was filed by Dyne Therapeutics with SEC on 2024-05-16. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Dyne Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Dyne Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Dyne Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Dyne Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Dyne Therapeutics Fundamental Analysis

We analyze Dyne Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

Dyne Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Dyne Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dyne Therapeutics stock to make a market-neutral strategy. Peer analysis of Dyne Therapeutics could also be used in its relative valuation, which is a method of valuing Dyne Therapeutics by comparing valuation metrics with similar companies.

Peers

Dyne Therapeutics Related Equities

MLYSMineralys Therapeutics,   0.39   
5.0%
STOKStoke Therapeutics   1.60   
23.0%
GLUEMonte Rosa   2.22   
32.0%
RVMDRevolution Medicines   2.38   
34.0%
CYTKCytokinetics   2.43   
35.0%
ERASErasca   3.05   
44.0%
EWTXEdgewise Therapeutics   3.10   
45.0%
PLRXPliant Therapeutics   3.35   
49.0%
DSGNDesign Therapeutics   3.70   
54.0%
CGEMCullinan Oncology   6.82   
100.0%
When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:
Check out Dyne Therapeutics Hype Analysis, Dyne Therapeutics Correlation and Dyne Therapeutics Performance.
To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.58)
Return On Assets
(0.40)
Return On Equity
(0.69)
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.